Fig. 2From: Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in AustriaProgression free survival analysis. Number at risk: 3 months: 8 (2), 6 months: 4 (3), 9 months: 1 (4), 12 months: 1 (4)Back to article page